Drug manufacturer’s dossier did not contain suitable data for any therapeutic indication Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal…
Source: IQWiG dossier assessment finds no added benefit of lixisenatide
Saturday, August 3, 2013
IQWiG dossier assessment finds no added benefit of lixisenatide
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment